Budget 2026-27 announced Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) with ₹10,000 crore over 5 years. The initiative targets domestic production of biologics and biosimilars for non-communicable diseases like cancer, diabetes, and autoimmune disorders. Key components: establishment of 3 new National Institutes of Pharmaceutical Education and Research (NIPER) and upgrading 7 existing ones; creation of a network of over 1,000 accredited Indian Clinical Trials sites; strengthening of CDSCO with a dedicated scientific review cadre to meet global approval timeframes. The scheme aims to position India as a global biopharma manufacturing hub, building on the country's existing strength as the 'pharmacy of the world' in generic medicines.
Budget 2026: Biopharma SHAKTI — ₹10,000 Crore to Make India Global Biomanufacturing Hub
Biopharma SHAKTI: ₹10,000 crore over 5 years; 3 new NIPERs; 1,000+ clinical trial sites; CDSCO strengthened; biologics/biosimilars focus.
Key facts
- Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) launched in Budget 2026-27 with ₹10,000 crore over 5 years
- Targets domestic production of biologics and biosimilars for cancer, diabetes, and autoimmune disorders
- 3 new NIPERs to be established and 7 existing ones to be upgraded
- Network of over 1,000 accredited Indian Clinical Trials sites to be created
- CDSCO to be strengthened with dedicated scientific review cadre to meet global approval timeframes
- Aims to position India as a global biopharma manufacturing hub, building on generic medicines strength
Mains angle
Q: Discuss the objectives and key components of the Biopharma SHAKTI scheme announced in Budget 2026 for making India a global biomanufacturing hub.
Answer (50 words):
Budget 2026-27 announced Biopharma SHAKTI with ₹10,000 crore over five years to target biologics and biosimilars for cancer, diabetes, and autoimmune disorders. Key components include three new NIPERs, upgradation of seven existing ones, over 1,000 accredited clinical trial sites, and strengthened CDSCO scientific review cadre for global approval timeframes.
Static prep for this topic
Read the permanent syllabus behind this story.
6-axis classification
Appears in these topics
Practice MCQ from this story
SolveTap an option below. Correct or incorrect feedback appears instantly.
What is the outlay for Biopharma SHAKTI announced in Budget 2026-27?
Biopharma SHAKTI received ₹10,000 crore over 5 years to develop India as a global biomanufacturing hub.
Source: The Week
Frequently asked questions
What is the Biopharma SHAKTI scheme announced in Budget 2026-27?
**Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge Technology and Innovation)** is a ₹10,000 crore initiative over 5 years announced in Budget 2026-27. It targets **domestic production of biologics and biosimilars** for non-communicable diseases like cancer, diabetes, and autoimmune disorders, aiming to make India a **global biopharma manufacturing hub**.
What are the key components of the Biopharma SHAKTI scheme?
Biopharma SHAKTI includes: **(1) 3 new NIPERs** established and **7 existing NIPERs upgraded**; **(2) Network of 1,000+ accredited Indian Clinical Trials sites**; **(3) CDSCO strengthened** with a dedicated scientific review cadre to meet global approval timeframes; **(4) Focus on biologics and biosimilars** for non-communicable diseases.
What is the significance of Biopharma SHAKTI for India's position in global pharma?
Biopharma SHAKTI builds on India's strength as the **pharmacy of the world in generic medicines** and extends it into **biologics and biosimilars** — the next generation of medicines for cancer, diabetes, and autoimmune diseases. The **₹10,000 crore over 5 years** moves India up the **pharmaceutical value chain** from generic generics to complex biological drugs.
What is CDSCO and how does Biopharma SHAKTI strengthen it?
**CDSCO (Central Drugs Standard Control Organisation)** is India's national regulatory authority for pharmaceuticals and medical devices. Biopharma SHAKTI strengthens CDSCO with a **dedicated scientific review cadre** to enable it to **match global regulatory approval timeframes** (US FDA, EMA), making India's biopharma approvals internationally competitive and faster.
How many new NIPERs are planned under Biopharma SHAKTI in Budget 2026-27?
Budget 2026-27 under **Biopharma SHAKTI** plans to establish **3 new NIPERs (National Institutes of Pharmaceutical Education and Research)** and **upgrade 7 existing NIPERs**. NIPERs are premier pharmaceutical research and education institutions that train scientists and researchers for the Indian pharmaceutical industry.
Was this useful?
Share corrections or missing exam angles with the editorial team.
Send feedback